Thursday, 18 Jan 2018

You are here

Jak Inhibition May Ameliorate Pruritus

Last week we reported the results of a metanalysis published in the Journal of Investigative Dermatology showing that certain agents are more effective in managing the pruritus of psoriasis, including the inhibitors of IL-17, Janus kinase (Jak), adalimumab and apremilast. (https://buff.ly/2j3Oq9I)

Further credence to the effects of Jak inhibition are found in a report from Cell, where researchers from the Dermatology division at the Washington University School of Medicine have examined the role of type 2 cytokines in the activation of sensory neurons that may be involved in pruritus.  

They note that clinical studies demonstrate that JAK inhibitors relieve chronic itching. The current report details five patients with chronic idiopathic pruritus who improved when given tofacitinib. Earlier treatment with other anti-inflammatory drugs failed to help their chronic itching, but within one month of taking tofacitinib, all five patients reported marked relief from severe itching.

These researchers showed that sensory neurons in mice and humans are activated by the type 2 cytokine, interleukin-4 (IL-4). They also showed IL-4 enhances neuronal responsiveness to multiple pruritogens and that sensory neuron-specific deletion of IL-4Rα or JAK1 reduces chronic itch.

The authors believe, "This study reveals an evolutionarily conserved paradigm in which the sensory nervous system employs classical immune signaling pathways to influence mammalian behavior."

Figure thumbnail fx1

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Approves Mepolizumab for Churg-Strauss (EGPA)

The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. 

EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults.

Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?

Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi). (Citation source: https://buff.ly/2zXyY2X)

BMS Featured Presentations from ACR 2017

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Biosimilars Projected to Yield $54 Billion in Savings

A primary projected advantage to biosimilar drugs development has been cost savings. A new study from the RAND Corporation suggests biosimilars could cut health care spending in the United States by $54 billion over the next decade. This number is nearly 20 percent greater than a similar study conducted three years ago by the same researchers. 

Patterns of Biologic Use During Autoimmune Pregnancy

While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.